Iovance Biotherapeutics (IOVA) News Today $3.06 -0.02 (-0.49%) Closing price 03:59 PM EasternExtended Trading$3.08 +0.02 (+0.82%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.9% on Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Trading Down 5.9% on Analyst DowngradeApril 17 at 2:40 PM | marketbeat.comIs Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17 at 3:43 AM | msn.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $5.00 at BarclaysBarclays cut their target price on Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating on the stock in a research note on Monday.April 16 at 4:17 PM | marketbeat.comGeode Capital Management LLC Raises Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Geode Capital Management LLC lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,871,420 shares of the biotechnology company's stock after purchasing an addApril 16 at 3:36 AM | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lessened its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 29.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,306,826 shares of thApril 16 at 3:20 AM | marketbeat.comBarclays Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock PriceApril 16 at 2:33 AM | americanbankingnews.comBarclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)April 16 at 1:19 AM | markets.businessinsider.comIovance Biotherapeutics price target lowered to $5 from $22 at BarclaysApril 15 at 8:17 PM | markets.businessinsider.comAlliancebernstein L.P. Acquires 134,269 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Alliancebernstein L.P. grew its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 765,399 shares of the biotechnology company's stock afApril 15 at 3:57 AM | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $20.25 Average PT from BrokeragesApril 15 at 1:46 AM | americanbankingnews.comIs Iovance Biotherapeutics a Millionaire-Maker?April 14 at 10:05 AM | fool.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have given a buy ratingApril 14 at 1:14 AM | marketbeat.comNorges Bank Purchases New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Norges Bank acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 416,237 shares of the biotechnology company's stock, vaApril 13, 2025 | marketbeat.comIovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.com4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall StreetApril 7, 2025 | fool.comRhenman & Partners Asset Management AB Purchases 182,948 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Rhenman & Partners Asset Management AB increased its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,235,448 shares of the biotechApril 7, 2025 | marketbeat.comVanguard Group Inc. Raises Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Vanguard Group Inc. lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,534,340 sharesApril 7, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week Low - Here's WhyIovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week Low - What's Next?April 6, 2025 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) is Orion Investment Co's 10th Largest PositionOrion Investment Co boosted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,060,755 shares of the biotechnology companyApril 6, 2025 | marketbeat.comCinctive Capital Management LP Takes $2.44 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Cinctive Capital Management LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 329,204 shares of the biotecApril 5, 2025 | marketbeat.comIovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market CorrectionApril 4, 2025 | finance.yahoo.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 4.5% - Time to Buy?Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 4.5% - Still a Buy?April 4, 2025 | marketbeat.comIovance: Less And Less Likely To Reap Reward From Its Pioneering WorkApril 3, 2025 | seekingalpha.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 8% - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 8% - Time to Sell?April 1, 2025 | marketbeat.comArtisan Partners Limited Partnership Sells 261,657 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Artisan Partners Limited Partnership lessened its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,542,168 shares of theMarch 30, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - Here's What HappenedIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low - Here's What HappenedMarch 28, 2025 | marketbeat.comIs Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket?March 25, 2025 | msn.comEquities Analysts Offer Predictions for IOVA Q1 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now anticipates that tMarch 24, 2025 | marketbeat.com1 Stock Worth Buying Near Its 52-Week Low, According to Wall StreetMarch 22, 2025 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week Low - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - What's Next?March 22, 2025 | marketbeat.com3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm NotMarch 22, 2025 | fool.comResearch Analysts Offer Predictions for IOVA FY2027 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria expects that the biotechnology company will post eMarch 22, 2025 | marketbeat.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)March 21, 2025 | globenewswire.comRaymond James Financial Inc. Purchases New Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Raymond James Financial Inc. purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,563,296 shares of the biotechnology company'sMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Charles Schwab Investment Management Inc. lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,989,340 shares of the biotechnology company's stockMarch 21, 2025 | marketbeat.comIovance Biotherapeutics Likely to Add Hundreds of New Jobs At Philadelphia Navy YardMarch 20, 2025 | msn.com124,449 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Haven Capital Group Inc.Haven Capital Group Inc. bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 124,449 shares of the biotechnology company's stock, valuedMarch 19, 2025 | marketbeat.comIovance: The Company Makes It Hard To Estimate Revenue GrowthMarch 18, 2025 | seekingalpha.comIs Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts?March 18, 2025 | msn.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Moderate Buy" from BrokeragesIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy ratingMarch 18, 2025 | marketbeat.comIovance Biotherapeutics (IOVA) Receives a Buy from Stifel NicolausMarch 17, 2025 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - Time to Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year Low - Time to Sell?March 14, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comIovance expects to add hundreds of jobs at Navy Yard cell therapy centerMarch 12, 2025 | bizjournals.comStifel Nicolaus Remains a Hold on Atara Biotherapeutics (ATRA)March 12, 2025 | markets.businessinsider.comDown Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?March 12, 2025 | msn.comIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low - Time to Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - What's Next?March 8, 2025 | marketbeat.comMelanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 6, 2025 | theglobeandmail.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% After Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% on Analyst DowngradeMarch 5, 2025 | marketbeat.comIovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings GuidanceMarch 4, 2025 | finance.yahoo.com Remove Ads Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Media Mentions By Week IOVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.560.80▲Average Medical News Sentiment IOVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼157▲IOVA Articles Average Week Remove Ads Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Today Vaxcyte News Today Amarin News Today Rhythm Pharmaceuticals News Today PTC Therapeutics News Today Zai Lab News Today Arcellx News Today Ultragenyx Pharmaceutical News Today Avidity Biosciences News Today Akero Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
